Israel-based mitral valve company MitrAssist beats its $600,000 target to raise $1 million in support of its valve-in-valve technology.

Early-stage MitrAssist whizzed by it’s hoped-for raise of $600,000, landing $1 million from angel and private investors in support of the company’s mitral valve implant.

MitrAssist, a spin-out of Tredline Group’s accelerator program, is developing what it calls a “valve-on-valve” approach to treat mitral regurgitation for patients too elderly or unstable for an invasive open-heart operation. The procedure places a mechanical valve on top of an ill-functioning mitral valve to re-establish proper blood flow.